Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer.

ABSTRACT: Breast cancer alone accounts for the majority of cancer deaths among women, with the most commonly diagnosed subtype being estrogen receptor positive (ER+). Survival has greatly improved for patients with ER+ breast cancer, due in part to the development of antiestrogen compounds, such as tamoxifen. While treatment of the primary disease is often successful, as many as 30% of patients will experience recurrence and metastasis, mainly due to developed endocrine therapy resistance. In this study, we discovered two tamoxifen combination therapies, with simeprevir and VX-680, that reduce the tumor burden in animal models of ER+ breast cancer more than either compound or tamoxifen alone. Additionally, these tamoxifen combinations reduced the expression of HER2, a hallmark of tamoxifen treatment

SUBMITTER: Zboril EK 

PROVIDER: S-EPMC10296623 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature